Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Accenture
Baxter
Cerilliant
UBS
Daiichi Sankyo
Federal Trade Commission
Fish and Richardson
AstraZeneca

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,574,622

« Back to Dashboard

Which drugs does patent 8,574,622 protect, and when does it expire?

Patent 8,574,622 protects NATESTO and is included in one NDA.

This patent has twenty-four patent family members in twenty-one countries.
Summary for Patent: 8,574,622
Title:Controlled release delivery system for nasal applications
Abstract: This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.
Inventor(s): Mattern; Claudia (Stans, CH)
Assignee: M & P Patent Aktiengesellschaft (Vaduz, LI)
Application Number:13/194,928
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 8,574,622

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Aytu Bioscience Inc NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,574,622

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03025769Nov 11, 2003

Non-Orange Book US Patents Family Members for Patent 8,574,622

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,784,882 Controlled release delivery system for nasal applications and method of treatment ➤ Sign Up
8,877,230 Controlled release delivery system for nasal applications ➤ Sign Up
9,238,072 Controlled release delivery system for nasal applications and method of treatment ➤ Sign Up
2,014,073,618 ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
US Army
Fuji
Johnson and Johnson
US Department of Justice
McKinsey
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.